We would love to hear your thoughts about our site and services, please take our survey here.
If that’s the case, Co-locating onto a strategic customer/supplier site has merit. I remember John saying a future vision would be a strategic location in Europe for producing Itaconic Acid. Maybe the capital spend is to vertically integrate…
Exciting times ahead.
Well, that covered a lot of bases. A 3.6M capital spend sounds intriguing. I remember JS saying in previous presentations saying to expand existing facilities is relatively low cost Capex (ca. 0.5M?) so this sounds more substantial. Maybe a capital investment in a JV manufacturing partner. Time will tell. Either way it is very encouraging the management team is looking way down the tracks and can see what is coming. Good also that the contingent consideration is out of the way, with Yvon Durant getting shy of 2M shares. JS and his team can now really concentrate on rolling out (hopefully!) lots of good news. BIoAsterix, superabsorbents, coatings inter alia.
Fair point Surfie. None of us have a crystal ball and stuff can & does happen with risks that sometimes come home to roost. If we were beyond break even - which has been a long time coming - I’d be a tad happier. I’ve not given up yet though on my 20p by (end of) ‘23. Hoping this year’s RNS’s march us towards that.
Hi all, at (slightly nervous!) times like this sometimes we need a reminder of what we actually have (I know I do) to help keep the faith; so here is one: an excerpt from a Nouryon Press Release in 2019 - not that long ago:
“The new range of polymers strengthens Nouryon’s position as a leader in the chelates industry,” Kuijpers said. “Establishing this unique position is of strategic importance and underlines our commitment to sustainable growth.”
Peter Nieuwenhuizen, Chief Technology Officer at Nouryon, added: “We are pleased to complete the first supply agreement under our collaboration with Itaconix around its novel itaconic acid polymer platform. We firmly believe in the power and potential of collaborative innovation. By partnering, we create even greater innovation opportunities to offer to our customers.”
John R. Shaw, CEO of Itaconix, said: “I am excited that our joint work with Nouryon over the last year has created this global opportunity for our polymers.”
Peter Nieuwenhuizen is now our chair.
Every single box is ticked for me AJP - apart from one:
The box which says:
Profitable Revenue Growth Curve Back on Track.
C‘mon Itaconix, it‘s no longer if but when.
Maybe we LTH’s should all offer ourselves as free commission only sales champions!
Slainte
Nice one Smart. Let’s hope we get really strong 2022 final results coming out soon. Maybe the sooner the better as far as the EXec team is concerned, as their last chance of a share award from current and expiring share bonus programme is based on average share price (it’s been low!) in 30 days prior to final results announcement, and revenue growth.
I think that’s a lot of tosh AJP. The only thing that really matters is evidence of continued (increasingly profitable) growth along the published - albeit delayed - revenue growth curve. Hopefully confirmed by the company in its next RNS. The share price movement seems to suggest that!
Well done for buying more Smart. Any lower and I might do the same. Interestingly, when sells are made, people often are not so vocal, like one poster - a bit of a tube - over on the ITX ADVFN board who told the world & its granny about his every purchase, but was silent on his sales & then stuck the boot into the company.
Onto more important things: glad to see this major player is also distributing Itaconix product & apologies if the info was already posted somewhere:
https://omyakinetik.com/wp-content/uploads/Neutralize-Natural-Deodorant-Formulation-Card.pdf
I concur JD - Revenues without sufficient margin - long term - is not good at all. Short term, I can accept there may be a case of lowering to get the product in. I looked at Croda & Nouryon GMs a while back and recall they were hi 30‘s/low 40‘s. Good enough for them, good enough for us!
I reckon late January WB. Of key interest to me is if the contingent liability of $1.1M gets paid in full by way of shares per the the management incentive programme, based on 2022 results. I hope it does - it means revenues are growing faster. And hopefully with a better GM.
Hi JD I’m only stating that IF on release of 2022 numbers, a share award based on revenue growth targets being met is due, then the number of shares awarded will be higher if the share price remains low. See RNS from June 20th 2016 for scheme details. AND 2022 numbers will bring to a close this scheme. So last chance for Exec Team to benefit from it.